Factors associated with initiation of bone-health medication among older adults in primary care in Ireland

Background: Adults at high risk of fragility fracture should be offered pharmacological treatment when not contraindicated, however under-treatment is common. Objective: This study aimed to investigate factors associated with bone-health medication initiation in older patients attending primary care. Design: Retrospective cohort study. Setting: 44 general practices in Ireland from 2011-2017. Subjects: Adults aged [≥]65 years who were naive to bone-health medication for 12 months. Methods: Overall fracture-risk (based on QFracture) and individual fracture-risk factors were described for patients initiated and not initiated onto medication and compared using generalised linear model regression with Poisson distribution. Results: Of 36,799 patients (51 % female, mean age 75.4 (SD=8.4)) included, 8% (n=2,992) were observed to initiate on bone-health medication during the study. One fifth of all patients (n=8,193) had osteoporosis or had high fracture-risk but only 21% of them (n=1,687) initiated on medication. Female sex, older age, state-funded health cover and osteoporosis were associated with initiation. Independently of osteoporosis and co-variates, high 5-year QFracture risk for hip (IRR=1.33 (95% CI=1.17-1.50), p<0.01) and all fractures (IRR=1.30 (95% CI=1.17-1.44), p<0.01) were associated with medication initiation. Previous fracture, rheumatoid arthritis, and corticosteroid use were associated with initiation, while liver, kidney, cardiovascular disease, diabetes and oestrogen-only hormone replacement therapy showed an inverse association. Conclusions: Bone-health medication initiation is targeted at patients at higher fracture-risk but much potential under-treatment remains, particularly in those >80 years and with co-morbidities. This may reflect clinical uncertainty in older multimorbid patients, and further research should explore decision-making in preventive bone medication prescribing.

[1]  Marrissa Martyn-St James,et al.  Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. , 2020, Health technology assessment.

[2]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[3]  J. Thistlethwaite,et al.  Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice , 2020, BMC Family Practice.

[4]  A. Gafter-Gvili,et al.  Risk for Infections During Treatment With Denosumab for Osteoporosis: a Systematic Review and Meta-analysis. , 2020, The Journal of clinical endocrinology and metabolism.

[5]  K. Johnell,et al.  Polypharmacy and injurious falls in older adults: a nationwide nested case-control study , 2019, Clinical epidemiology.

[6]  J. Quinlan,et al.  Changing trends in the mortality rate at 1-year post hip fracture - a systematic review , 2019, World journal of orthopedics.

[7]  H. E. van der Horst,et al.  Factors related to intentional non-initiation of bisphosphonate treatment in patients with a high fracture risk in primary care: a qualitative study , 2018, BMC Family Practice.

[8]  C. Cooper,et al.  Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial , 2017, The Lancet.

[9]  C. Cooper,et al.  UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.

[10]  K. Robinson,et al.  Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease , 2017, Annals of Internal Medicine.

[11]  S. Greenspan,et al.  Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Geriatrics Society.

[12]  Ran D Balicer,et al.  External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study , 2017, British Medical Journal.

[13]  S. Davis,et al.  A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. , 2016, Health technology assessment.

[14]  L. A. A. Santos,et al.  Diagnosis and Management of Cirrhosis-Related Osteoporosis , 2016, BioMed research international.

[15]  Lorena Saletti-Cuesta,et al.  The relevance of gender in the care of hip fracture patients. , 2016, International journal of orthopaedic and trauma nursing.

[16]  A. Pabst,et al.  Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw , 2016, Dentistry journal.

[17]  M. Price,et al.  The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis. , 2016, Health technology assessment.

[18]  E. Siris,et al.  Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage , 2015, Clinical interventions in aging.

[19]  David Moher,et al.  The REporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) Statement: Methods for Arriving at Consensus and Developing Reporting Guidelines , 2015, PloS one.

[20]  L. Carmona,et al.  The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis , 2015, Annals of the rheumatic diseases.

[21]  James R. Rogers,et al.  Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis , 2015, PloS one.

[22]  J. Reginster,et al.  A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. , 2015, The Journal of clinical endocrinology and metabolism.

[23]  L. Melton,et al.  Trends in Fracture Incidence: A Population‐Based Study Over 20 Years , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  R. Eastell,et al.  Osteoporosis in men: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.

[25]  Carol Coupland,et al.  Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study , 2012, BMJ : British Medical Journal.

[26]  J. Kanis,et al.  From relative risk to absolute fracture risk calculation: The FRAX algorithm , 2009, Current osteoporosis reports.

[27]  L. Ji,et al.  Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. , 2019, Bone.

[28]  S. Straus,et al.  Complex interventions can increase osteoporosis investigations and treatment: a systematic review and meta-analysis , 2017, Osteoporosis International.

[29]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[30]  C. Cunningham,et al.  Awareness and management of osteoporosis among General Practitioners in Ireland , 2015 .